News

Inhaled Revatio (sildenafil) appears to be superior to current oral forms of this approved pulmonary arterial hypertension (PAH) treatment by allowing for lower doses and potentially fewer systematic side effects, researchers report. They also recommend that a nebulized form of Revatio be produced and moved into clinical testing in patients. The study reporting this finding, “Inhaled Sildenafil As An…

Patients with pulmonary arterial hypertension (PAH) caused by connective tissue disease benefit from treatment with Adcirca (tadalafil), but their outcomes aren’t as good as patients with idiopathic PAH, an analysis of data from two clinical trials indicates. Safety was a particular problem with connective tissue disease patients, the evaluation…

Paris-based biotechnology company Mifcare is getting support from the French pulmonary hypertension patients’ association HTaPFrance for the development of new anti-inflammatory therapies for pulmonary arterial hypertension (PAH). Melanie Gallant-Dewavrin, director of HTaPFrance, said promoting research to fight PAH is one of her association’s goals, “which is why I do not hesitate to…

Eliminating a long noncoding RNA reduced heart-muscle enlargement in mice with pulmonary hypertension (PH), according to a study. The RNA, known as MALAT1, balances the turnover — or production, growth and death — of smooth muscle cells lining blood vessels. MALAT1 stands for metastasis-associated lung adenocarcinoma transcript 1. The study, “…

A recent article that presented case studies of three patients with rheumatoid arthritis-associated pulmonary hypertension (PH), highlights the diversity of the underlying causes of the disease, and emphasizes the importance of diagnosing it early. The study “Rheumatoid arthritis associated pulmonary hypertension: Clinical challenges reflecting the diversity of pathophysiology”…

Screening patients with systemic sclerosis (SSc) for pulmonary arterial hypertension (PAH) may help identify patients with both conditions sooner to start appropriate treatments, ensuring a better outcome, according to new research. The study, “Epidemiology And Disease Characteristics Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension: Results From A Real-Life Screening Programme,” was published in…

Northwestern Medicine’s Pulmonary Vascular Disease Program has won accreditation as a Comprehensive Care Center by the Pulmonary Hypertension Association (PHA), in recognition of its excellence in diagnosis, research and clinical care of PH patients. To earn the accreditation, the program, which is led by Stuart Rich,…